FR19C1058I2 - STEM/EMBRYONIC CELL MOBILIZATION METHODS - Google Patents

STEM/EMBRYONIC CELL MOBILIZATION METHODS

Info

Publication number
FR19C1058I2
FR19C1058I2 FR19C1058C FR19C1058C FR19C1058I2 FR 19C1058 I2 FR19C1058 I2 FR 19C1058I2 FR 19C1058 C FR19C1058 C FR 19C1058C FR 19C1058 C FR19C1058 C FR 19C1058C FR 19C1058 I2 FR19C1058 I2 FR 19C1058I2
Authority
FR
France
Prior art keywords
sub
atoms
nitrogen
formula
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1058C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR19C1058(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of FR19C1058I1 publication Critical patent/FR19C1058I1/fr
Application granted granted Critical
Publication of FR19C1058I2 publication Critical patent/FR19C1058I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Abstract

Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z' (1) or pharmaceutically acceptable salt thereof wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system; or Z is of formula (a), wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1-20 atoms, Z' may be embodied in a form as defined by Z above, or alternatively may be of the formula -N(R)-(CR<sub>2</sub>)<sub>n</sub>-X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; "linker" represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulphur atoms.
FR19C1058C 2001-07-31 2019-10-10 STEM/EMBRYONIC CELL MOBILIZATION METHODS Active FR19C1058I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US38215502P 2002-05-20 2002-05-20
PCT/US2002/024212 WO2003011277A2 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
EP02750370A EP1411918B1 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
FR19C1058I1 FR19C1058I1 (en) 2019-11-22
FR19C1058I2 true FR19C1058I2 (en) 2020-10-23

Family

ID=26976666

Family Applications (2)

Application Number Title Priority Date Filing Date
FR12C0042C Active FR12C0042I1 (en) 2001-07-31 2012-06-28 METHODS OF MOBILIZING STEM/EMBRYONIC CELLS
FR19C1058C Active FR19C1058I2 (en) 2001-07-31 2019-10-10 STEM/EMBRYONIC CELL MOBILIZATION METHODS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR12C0042C Active FR12C0042I1 (en) 2001-07-31 2012-06-28 METHODS OF MOBILIZING STEM/EMBRYONIC CELLS

Country Status (29)

Country Link
US (9) US6987102B2 (en)
EP (3) EP2371361B1 (en)
JP (2) JP5137288B2 (en)
KR (2) KR100996378B1 (en)
CN (2) CN102302493B (en)
AT (1) ATE538785T1 (en)
AU (1) AU2002318927B2 (en)
BE (1) BE2019C544I2 (en)
BR (1) BRPI0211570B8 (en)
CA (1) CA2455559C (en)
CY (4) CY1112633T1 (en)
DK (2) DK1411918T3 (en)
ES (2) ES2380009T3 (en)
FR (2) FR12C0042I1 (en)
HK (1) HK1063005A1 (en)
HU (1) HUP0402360A2 (en)
IL (2) IL159312A0 (en)
LT (2) LT2371361T (en)
LU (2) LU92033I2 (en)
MX (1) MXPA04000982A (en)
NL (2) NL300537I2 (en)
NO (4) NO336989B1 (en)
NZ (1) NZ530169A (en)
PL (1) PL364673A1 (en)
PT (2) PT1411918E (en)
RU (1) RU2309741C2 (en)
SI (2) SI2371361T1 (en)
WO (1) WO2003011277A2 (en)
ZA (1) ZA200400658B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
PT1411918E (en) 2001-07-31 2012-03-06 Genzyme Global S A R L Methods to mobilize progenitor/stem cells
JP4556020B2 (en) 2001-12-21 2010-10-06 ジェンザイム・コーポレーション Chemokine receptor-bound heterocyclic compounds with high efficacy
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR101160698B1 (en) * 2003-06-27 2012-06-28 아사히 가세이 가부시키가이샤 Cell differentiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
JP2007535479A (en) 2003-08-13 2007-12-06 チルドレンズ ホスピタル メディカル センター Chimeric peptide for regulating GTPase
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
JP2008519052A (en) 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション Optimum behavior of human migratory cells by drugs
ES2539490T3 (en) 2005-06-13 2015-07-01 Cleveland Biolabs, Inc. Methods to protect against apoptosis using lipopeptides
WO2007022523A2 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
EP1924606A4 (en) * 2005-08-25 2010-01-13 Repair Technologies Inc Devices, compositions and methods for the protection and repair of cells and tissues
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
CA2643209A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
WO2007108689A2 (en) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Method for induction of differentiation of stem and progenitor cells
RU2009108289A (en) * 2006-08-07 2010-09-20 Джензим Корпорейшн (Us) COMBINED THERAPY
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20110245265A1 (en) * 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
WO2011053700A1 (en) 2009-10-28 2011-05-05 Henry Ford Health System Methods to mitigate injury from radiation exposure
CN101716167B (en) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 Use of saturated amine compound in preparation of medicaments for mobilizing peripheral blood hematopoietic stem cells
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX365242B (en) 2011-05-16 2019-05-28 Genzyme Corp Use of cxcr4 antagonists.
EP2968563A4 (en) * 2013-03-15 2016-11-30 Leonard B Miller Combination therapy to improve soft tissue healing, fat graft healing, endochondral bone healing and osteointegration
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
JP2018531229A (en) 2015-09-18 2018-10-25 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル Local delivery of anti-fugetactic agents for the treatment of cancer
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
SI3393468T1 (en) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CN109153722A (en) 2016-04-08 2019-01-04 X4 制药有限公司 Method for treating cancer
US11433048B2 (en) * 2016-06-16 2022-09-06 Centre National De La Recherche Scientifique CXCR4 receptor-binding compounds useful for increasing interferon level
CN116554168A (en) 2016-06-21 2023-08-08 X4 制药有限公司 CXCR4 inhibitors and uses thereof
CN109641838A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
CN109640988A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
WO2018049124A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018049118A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
WO2018049120A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3083783A1 (en) * 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
CN111741752A (en) * 2017-12-19 2020-10-02 Gpcr治疗公司 GPCR heteromer inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (en) 1987-08-24 1989-03-16 Schering Ag MULTI-CORE SUBSTITUTED COMPLEX ILLUMINATORS, COMPLEX AND COMPLEX SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
FR2644453A1 (en) 1989-03-20 1990-09-21 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF MONOFUNCTIONALIZED CYCLIC TETRAMINES
ES2116291T3 (en) 1989-10-23 1998-07-16 Nycomed Salutar Inc CHELATING AGENTS OF METALS IN MULTIPLE SITES.
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
FR2672051B1 (en) 1991-01-24 1993-05-21 Guerbet Sa NOVEL NITROGEN MACROCYCLIC LIGANDS, PREPARATION METHOD, POLYMETALLIC COMPLEXES, DIAGNOSTIC AND THERAPEUTIC COMPOSITION.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DE69309487T2 (en) 1992-11-13 1997-10-23 Univ Washington PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
JPH08127539A (en) * 1994-10-31 1996-05-21 Ajinomoto Co Inc Human il-11-containing peripheral blood stem cell proliferator
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (en) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd Medicine for increasing number of hematopoietic stem cells in peripheral blood
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
AU770896C (en) * 1998-09-29 2006-09-07 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2731416A1 (en) * 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
AU4696899A (en) * 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
JP2002529502A (en) * 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション Treatment of thrombocytopenia
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
JP2003524620A (en) 1999-03-24 2003-08-19 アノーメッド インコーポレイティド Chemokine receptor binding heterocyclic compounds
JP2002543126A (en) * 1999-05-03 2002-12-17 スミスクライン・ビーチャム・コーポレイション CXCR-4 receptor antagonist-thrombopoietin mimic
EP1244648B1 (en) * 1999-12-17 2009-04-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
WO2001085196A2 (en) 2000-05-09 2001-11-15 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US20040131585A1 (en) * 2000-06-05 2004-07-08 Silviu Itescu Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
BR0113932A (en) 2000-09-15 2003-06-24 Anormed Inc Heterocyclic compounds that bind to the chemokine receptor
PL360932A1 (en) 2000-09-15 2004-09-20 Anormed Inc. Chemokine receptor binding heterocyclic compounds
JP2004508421A (en) 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド Chemokine receptor binding heterocyclic compounds
DE60136476D1 (en) 2000-09-29 2008-12-18 Anormed Inc NITROGENIC CYCLIC POLYAMINES AND THEIR COMPOUNDS
CN1264498C (en) 2001-01-23 2006-07-19 P&G克莱罗尔公司 Primary intermediates for oxidative coloration of hair
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
PT1411918E (en) 2001-07-31 2012-03-06 Genzyme Global S A R L Methods to mobilize progenitor/stem cells
JP4556020B2 (en) 2001-12-21 2010-10-06 ジェンザイム・コーポレーション Chemokine receptor-bound heterocyclic compounds with high efficacy
DE102014206089B4 (en) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Domestic refrigerating appliance with a dispenser unit with two closure elements on a delivery channel

Also Published As

Publication number Publication date
LU92033I9 (en) 2019-01-03
LUC00139I2 (en) 2021-02-10
EP2371361B1 (en) 2019-08-07
LTPA2019018I1 (en) 2019-12-10
HUP0402360A2 (en) 2005-02-28
BRPI0211570B8 (en) 2021-05-25
EP1411918B1 (en) 2011-12-28
FR19C1058I1 (en) 2019-11-22
BE2019C544I2 (en) 2021-07-19
ATE538785T1 (en) 2012-01-15
JP5137288B2 (en) 2013-02-06
AU2002318927B2 (en) 2007-01-04
US20190216773A1 (en) 2019-07-18
EP1411918A4 (en) 2007-11-14
EP2371361A1 (en) 2011-10-05
BR0211570A (en) 2004-07-13
CN1561208A (en) 2005-01-05
BRPI0211570B1 (en) 2020-01-28
CN102302493B (en) 2015-08-12
KR100996378B1 (en) 2010-11-25
NL301031I1 (en) 2020-02-05
NO344632B1 (en) 2020-02-17
SI1411918T1 (en) 2012-04-30
US7897590B2 (en) 2011-03-01
SI2371361T1 (en) 2019-10-30
RU2309741C2 (en) 2007-11-10
NZ530169A (en) 2007-04-27
US20110129448A1 (en) 2011-06-02
CY1112633T1 (en) 2015-08-05
LUC00139I1 (en) 2019-11-27
NO20150674A1 (en) 2015-05-27
CY1122199T1 (en) 2020-05-29
ZA200400658B (en) 2005-07-27
US20030130250A1 (en) 2003-07-10
US20170049747A1 (en) 2017-02-23
JP2004538303A (en) 2004-12-24
EP3632425A1 (en) 2020-04-08
WO2003011277A3 (en) 2003-05-22
PL364673A1 (en) 2004-12-13
FR12C0042I1 (en) 2012-08-10
CY2019038I2 (en) 2020-05-29
CA2455559C (en) 2012-01-10
NL300537I2 (en) 2017-02-02
US20060193826A1 (en) 2006-08-31
CA2455559A1 (en) 2003-02-13
CN1561208B (en) 2010-11-10
CY2019038I1 (en) 2020-05-29
DK2371361T3 (en) 2019-08-19
US20150246019A1 (en) 2015-09-03
DK1411918T3 (en) 2012-04-23
NL301031I2 (en) 2020-07-20
ES2380009T3 (en) 2012-05-07
CY2012017I1 (en) 2015-08-05
NO336989B1 (en) 2015-12-14
US6987102B2 (en) 2006-01-17
KR20090130152A (en) 2009-12-17
CY2012017I2 (en) 2015-08-05
RU2004105961A (en) 2005-03-20
IL159312A (en) 2015-05-31
NO20040407L (en) 2004-03-19
LTC2371361I2 (en) 2021-09-27
IL159312A0 (en) 2004-06-01
EP1411918A2 (en) 2004-04-28
NO2016011I1 (en) 2016-06-10
ES2742730T3 (en) 2020-02-17
PT2371361T (en) 2019-09-10
US20080063624A1 (en) 2008-03-13
WO2003011277A2 (en) 2003-02-13
US7935692B2 (en) 2011-05-03
PT1411918E (en) 2012-03-06
NO2020003I1 (en) 2020-03-05
CN102302493A (en) 2012-01-04
US20060223180A1 (en) 2006-10-05
MXPA04000982A (en) 2004-04-20
LT2371361T (en) 2019-09-10
KR20040020075A (en) 2004-03-06
HK1063005A1 (en) 2004-12-10
US20130273009A1 (en) 2013-10-17
JP2008195730A (en) 2008-08-28
LU92033I2 (en) 2012-08-27

Similar Documents

Publication Publication Date Title
FR19C1058I2 (en) STEM/EMBRYONIC CELL MOBILIZATION METHODS
AP1497A (en) Methods and compositions to enhance white blood cell count.
HUP0004259A2 (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof
KR920012082A (en) Novel amino and nitro containing tricyclic compounds useful as ACE inhibitors
ES2164164T3 (en) USEFUL AMINOTETRAZOL DERIVATIVES AS NITRICO SINTASA OXIDE INHIBITORS.
EA200501148A1 (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
EA200000431A3 (en) New substituted dimeric compounds, a process for their preparation and pharmaceutical compositions containing them
ATE277010T1 (en) BIS-INDOLE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS
DE69727305D1 (en) USE OF NEUROGEN-DISABLED COMPOUNDS AND COMPOSITIONS
FR2795412B1 (en) NOVEL QUATERNARY AMMONIUM DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1999023092A3 (en) 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
WO2007106063A3 (en) Methods for increasing blood flow and/or promoting tissue regeneration
EA200001157A2 (en) New substituted (dihydro)benzoxazime and (dihydro)benzothiazine compounds, a process for their preparation and pharmaceutical compositions containing them